CLINICAL TRIALS PROFILE FOR FOSAMAX

All Clinical Trials for FOSAMAX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000400 ↗	Alendronate and/or Parathyroid Hormone for Osteoporosis	Completed	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 2	1999-08-01	This study looks at the effects of two medications, alendronate and parathyroid hormone, on bone mass and on bone formation and bone breakdown in women with osteoporosis. We will randomly select postmenopausal women who have osteoporosis to receive laboratory-produced human parathyroid hormone (hPTH), or alendronate, or both for 2.5 years. Study participants will return to the study center periodically to have their bone mass measured and to give blood and urine samples for tests of bone formation and breakdown and for other laboratory tests. Those who complete the study are eligible for one or two 12 month extension studies.
NCT00000400 ↗	Alendronate and/or Parathyroid Hormone for Osteoporosis	Completed	Massachusetts General Hospital	Phase 2	1999-08-01	This study looks at the effects of two medications, alendronate and parathyroid hormone, on bone mass and on bone formation and bone breakdown in women with osteoporosis. We will randomly select postmenopausal women who have osteoporosis to receive laboratory-produced human parathyroid hormone (hPTH), or alendronate, or both for 2.5 years. Study participants will return to the study center periodically to have their bone mass measured and to give blood and urine samples for tests of bone formation and breakdown and for other laboratory tests. Those who complete the study are eligible for one or two 12 month extension studies.
NCT00000412 ↗	Osteoporosis Prevention After Heart Transplant	Completed	Merck Sharp & Dohme Corp.	Phase 3	1997-09-01	During the first year after a heart transplant, people often rapidly lose bone from their spine and hips. About 35 percent of people who receive heart transplants will suffer broken bones during the first year after transplantation. This study will compare the safety and effectiveness of the drug alendronate (Fosamax) and the active form of vitamin D (calcitriol) in preventing bone loss at the spine and hip after a heart transplant. In this study, people who have had a successful heart transplant will receive either active alendronate and a "dummy pill" instead of calcitriol, or active calcitriol and a dummy pill instead of alendronate for the first year after their transplant, starting within 1 month after transplant surgery. We will measure bone density in the hip and spine at the start of the study and after 6 and 12 months, and will also check for broken bones in the spine. This research should lead to ways of preventing this crippling form of osteoporosis.
NCT00000412 ↗	Osteoporosis Prevention After Heart Transplant	Completed	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 3	1997-09-01	During the first year after a heart transplant, people often rapidly lose bone from their spine and hips. About 35 percent of people who receive heart transplants will suffer broken bones during the first year after transplantation. This study will compare the safety and effectiveness of the drug alendronate (Fosamax) and the active form of vitamin D (calcitriol) in preventing bone loss at the spine and hip after a heart transplant. In this study, people who have had a successful heart transplant will receive either active alendronate and a "dummy pill" instead of calcitriol, or active calcitriol and a dummy pill instead of alendronate for the first year after their transplant, starting within 1 month after transplant surgery. We will measure bone density in the hip and spine at the start of the study and after 6 and 12 months, and will also check for broken bones in the spine. This research should lead to ways of preventing this crippling form of osteoporosis.
NCT00000412 ↗	Osteoporosis Prevention After Heart Transplant	Completed	Columbia University	Phase 3	1997-09-01	During the first year after a heart transplant, people often rapidly lose bone from their spine and hips. About 35 percent of people who receive heart transplants will suffer broken bones during the first year after transplantation. This study will compare the safety and effectiveness of the drug alendronate (Fosamax) and the active form of vitamin D (calcitriol) in preventing bone loss at the spine and hip after a heart transplant. In this study, people who have had a successful heart transplant will receive either active alendronate and a "dummy pill" instead of calcitriol, or active calcitriol and a dummy pill instead of alendronate for the first year after their transplant, starting within 1 month after transplant surgery. We will measure bone density in the hip and spine at the start of the study and after 6 and 12 months, and will also check for broken bones in the spine. This research should lead to ways of preventing this crippling form of osteoporosis.
NCT00001720 ↗	Treatment of Childhood Osteoporosis With Alendronate (Fosamax)	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2	1998-03-01	Bones grow and stay strong through a continuous process of formation (building) and resorption (break down). When more bone is formed than resorbed, the density (level of calcium) in bone increases and the bones become stronger. However, if more bone is resorbed than formed the density of bone decreases and the bones become weak. This condition is called osteoporosis. Osteoporosis is a rare but serious condition in children. Childhood osteoporosis can occur without a known cause (idiopathic juvenile osteoporosis). Children with osteoporosis suffer from pain, inability to stay active, and increased amounts of broken bones, including fractures of the spine. Even mild childhood osteoporosis may have long-term consequences since individuals who achieve a less than normal bone composition (peak bone mass) during the first 20-30 years of life may be at an increased risk for osteoporosis as adults. Alendronate (Fosamax) is a drug that works by stopping bone resorption (break down). It has been used to treat post-menopausal osteoporosis, male osteoporosis and adults with osteoporosis due to long-term steroid therapy. The goal of this study is to determine the effectiveness of alendronate in children with idiopathic juvenile osteoporosis. Researchers believe that children treated with alendronate will improve bone strength and decrease the amount of fractures caused by osteoporosis.
NCT00005006 ↗	Parathyroid Hormone (PTH) With Alendronate for Osteoporosis	Completed	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 2	1987-09-01	This study investigates the effectiveness of parathyroid hormone (PTH) in combination with alendronate, a standard treatment for osteoporosis that blocks or reduces bone loss. We are using alendronate because it may help protect patients against any possible harmful effects of PTH in cortical bone such as the long bones or hip. We are testing two different treatment schedules of PTH-one in which we give PTH daily and one in which we give PTH for 3 out of every 6 months in a cyclical fashion. The entire study is 21 months long; the active treatment period is 18 months with a 6-month followup period. The main effects we will look for in this study are changes in body chemicals that are signs of bone formation or bone breakdown, and changes in bone density throughout the skeleton. We will randomly assign all study participants, who are women aged 50 and over, to either stay on alendronate alone, receive daily continuous PTH plus alendronate, or receive daily PTH for 3 months out of every 6 for a total of three separate 3-month cycles of PTH plus daily alendronate.

Clinical Trial Conditions for FOSAMAX

Condition Name

Condition Name for FOSAMAX
Intervention	Trials
Osteoporosis	35
Healthy	4
Postmenopausal Osteoporosis	3
Osteopenia	3

Condition MeSH

Condition MeSH for FOSAMAX
Intervention	Trials
Osteoporosis	45
Bone Diseases, Metabolic	10
Osteoporosis, Postmenopausal	10
Spinal Cord Injuries	3

Clinical Trial Locations for FOSAMAX

Trials by Country

Trials by Country for FOSAMAX
Location	Trials
United States	59
Canada	11
Brazil	10
Spain	6
Mexico	6

Trials by US State

Trials by US State for FOSAMAX
Location	Trials
New York	7
Massachusetts	6
California	5
Illinois	5
Maryland	4

Clinical Trial Progress for FOSAMAX

Clinical Trial Phase

Clinical Trial Phase for FOSAMAX
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	18
Phase 3	14

Clinical Trial Status

Clinical Trial Status for FOSAMAX
Clinical Trial Phase	Trials
Completed	45
Terminated	6
Recruiting	5

Clinical Trial Sponsors for FOSAMAX

Sponsor Name

Sponsor Name for FOSAMAX
Sponsor	Trials
Merck Sharp & Dohme Corp.	13
Amgen	5
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	4

Sponsor Type

Sponsor Type for FOSAMAX
Sponsor	Trials
Other	70
Industry	31
NIH	13

FOSAMAX (alendronate) clinical trials update, market analysis, and exclusivity/generic outlook

Last updated: July 27, 2026

Executive summary

• FOSAMAX (alendronate sodium) is a long-established bisphosphonate for osteoporosis and related bone disorders. Commercial scale is limited by mature use patterns and ongoing generic competition in the U.S.
• Clinical-trials activity is low relative to launch-era products. Current research is dominated by comparative effectiveness, adherence/persistence, and real-world evidence rather than new pivotal phase programs.
• Market outlook is driven by: (1) prevalence of osteoporosis, (2) payer pressure and wholesale competition from generics, and (3) safety and dosing adherence dynamics that affect persistence.
• For market projection and competitive planning, the key gating item is U.S. regulatory and patent status. For FOSAMAX, mainline U.S. availability is effectively off-patent and faces broad generic entry already in place, limiting upside from new exclusivity creation.

---

FOSAMAX clinical trials update: what trials are ongoing or recently completed?

Quick answer: Trial activity for alendronate has shifted toward real-world, comparative, and adherence-focused studies, with fewer new late-stage efficacy trials.

What trial types are most active for alendronate?

1. Head-to-head or class-comparator studies

   • Typical design: observational comparative effectiveness across bisphosphonates (oral and sometimes IV comparators such as zoledronic acid).
   • Endpoints: fracture incidence proxies, adherence, persistence, discontinuation due to GI events, and switching.

2. Adherence and dosing-behavior studies

   • Use patterns for weekly dosing (missed dose frequency) and counseling interventions.
   • Metrics: medication possession ratio, persistence duration, and discontinuation rates.

3. Safety monitoring and risk stratification

   • Ongoing pharmacovigilance and cohort monitoring around known bisphosphonate risks (GI tolerability, atypical femur fracture signals, osteonecrosis of the jaw).
   • Many studies leverage claims databases or registry data rather than traditional randomized phase work.

4. Subpopulation endpoints

   • Elderly cohorts, chronic kidney disease stratification, and fracture-risk enrichment groups.
   • Emphasis is on outcomes that drive payer and guideline decisions.

Are there any new pivotal phase programs?

No high-impact, clearly delineated “new pivotal” registration program is associated with alendronate’s brand competitive cycle in the current market. Most activity does not change the competitive landscape in the way a Phase 3 efficacy readout would. The practical effect: clinical updates generally support labeling maintenance and safety framing rather than creating new exclusivity value.

Business implication: For licensing or partnering, alendronate brand value does not hinge on fresh Phase 3 catalysts. Value rests on formulation life-cycle moves (if any) and the ability to defend a niche through distribution, contracting, and patient access, not on new clinical registrations.

---

What patents protect FOSAMAX (alendronate sodium) in the U.S., and how many are still relevant?

Quick answer: The core active ingredient is off original-brand exclusivity; the live patent estate (if any) tends to be formulation, method-of-use, or secondary patents that do not typically create full market blocking against generic alendronate.

How the patent estate typically breaks down for older bisphosphonates

• Active ingredient / composition of matter: historically limited term, already expired for alendronate brand cycle.
• Method-of-use: may have older protected indications; practical enforcement depends on current Orange Book listings and whether generics can “design around.”
• Formulation / processing: can be incremental but rarely blocks a broad generic market once the foundational generic is established.
• Manufacturing: often not a dominant barrier once process patents expire or are not listed.

Orange Book status and blocking relevance

FOSAMAX’s competitive environment in the U.S. is already shaped by extensive generic availability. For business planning, focus should be on:

• whether any listed patents remain unexpired for the specific dosage forms still marketed under the brand,
• whether they are relevant to Paragraph IV litigation history,
• whether any “skinny label” or carved indication allows generic freedom even if some method-of-use claims persist.

Business implication: From a market competition perspective, the relevant question is not “how many patents exist,” but “which patents are Orange Book-listed and enforceable against current generic entry.” With FOSAMAX, the brand-to-generic gap is not typically maintained by active patent exclusivity.

---

When does FOSAMAX lose exclusivity, and when is the last patent expiry?

Quick answer: FOSAMAX is no longer protected by original active-ingredient patent exclusivity, and U.S. market access is dominated by long-established generic alendronate.

Practical exclusivity timeline for business forecasting

• Original exclusivity tied to earliest filings has already lapsed.
• Secondary patents (method-of-use, formulation, or manufacturing) may extend in some form, but they generally do not restore brand exclusivity against full generic products.

Business implication: For projection modeling, treat FOSAMAX as structurally exposed to generic pricing rather than as a product waiting for a patent-driven brand protection window to end.

---

What patent litigation affects FOSAMAX, including Paragraph IV challenges and settlements?

Quick answer: Patent litigation associated with older bisphosphonates typically occurred during the initial waves of generic approval. For current market conditions, incremental litigation events are not a primary driver of near-term brand dynamics for FOSAMAX.

What to look for in any remaining litigation record

• Whether any Orange Book patents still have active disputes tied to specific strengths or dosage forms.
• Whether litigation produced:
  • agreed carve-outs,
  • “design-around” labeling terms,
  • delayed launch commitments,
  • or settlement-triggered entry dates.

Business implication: For market forecasting and licensing strategy, litigation is best treated as a historical input for pricing and shelf presence rather than a forward-looking catalyst, unless a current Orange Book patent dispute is active for the specific brand dosage form.

---

What is the Orange Book status of FOSAMAX, and which strengths are listed?

Quick answer: FOSAMAX’s Orange Book listings reflect its marketed strengths and any listed patents. The U.S. market is still competitive, indicating that Orange Book-listed patents (if present) are not currently maintaining full brand exclusivity.

Dosage-form focus for competitive analysis

For planning, segmentation should track:

• oral tablet strengths offered under the brand,
• any strength-specific labeling differences tied to method-of-use claims,
• and whether generics cover each strength without carve-outs.

Business implication: Generic pressure is usually strength-agnostic for older platforms, but pricing can vary by strength based on formulation generic count and payer mix.

---

How does FOSAMAX compare with competing osteoporosis drugs for market position (revenue, dosing, adherence, payer preference)?

Quick answer: As an oral weekly bisphosphonate, alendronate competes primarily on low acquisition cost, payer preference for generics, and real-world adherence constraints driven by GI tolerability and administration technique.

Competitive set

• Other oral bisphosphonates: risedronate, ibandronate.
• IV option: zoledronic acid (market access often favored where adherence is poor or where dose convenience beats oral constraints).
• Non-bisphosphonate alternatives:
  • denosumab (Prolia) for adherence and efficacy considerations,
  • teriparatide/abaloparatide and romosozumab in higher-acuity cohorts.

What tends to shift prescriptions away from oral alendronate?

• GI side effects and discontinuation.
• Patient preference for less frequent dosing (IV or subQ).
• Prescriber preference driven by fracture-risk profile and adherence history.

Business implication: Alendronate’s market is resilient where payers require low-cost therapy, but it faces share erosion in segments that can access premium branded or long-interval therapies.

---

FOSAMAX market analysis: who buys it, how is it priced, and what drives volume?

Quick answer: Demand is driven by osteoporosis prevalence, guideline adoption, and payer-driven generic purchasing, with volume constrained by adherence and persistence.

Key demand drivers

• Epidemiology: aging population increases osteoporosis burden.
• Guideline and formulary:
  • First-line therapy in many settings is low-cost oral bisphosphonates when appropriate.
  • Prior authorization can exist but is typically less restrictive for generics.
• Adherence mechanics:
  • Weekly oral dosing can improve adherence vs daily regimens, but requires administration technique (fasting, water-only, upright).
• Safety monitoring:
  • Real-world management and discontinuation after adverse events reduce persistence.

Key supply and pricing dynamics

• Generic saturation reduces branded pricing power.
• Brand marketing and contracting can preserve some share but not to the level observed pre-generic entry.

Business implication: Forecast models should be built on payer mix and persistence cohorts, not on new patient initiation alone.

---

How will FOSAMAX revenue evolve over the next 5 years (market projection scenarios)?

Quick answer: Over a 5-year horizon, branded revenue is likely to remain pressured by generic penetration and cost containment. Total therapeutic market growth follows epidemiology, but brand share typically declines or stabilizes at low levels.

Scenario framework for projection

• Base case

  • Modest total market growth tied to osteoporosis prevalence.
  • Brand share held through contracting, patient assistance remnants (where applicable), and pharmacy benefit design.
  • Revenue growth near zero to low single digits, with sensitivity to generic pricing moves.

• Downside case

  • Intensified formulary preferencing of generic-only lists.
  • Additional erosion from “adherence-improvement” shifts toward less frequent dosing options.
  • Brand revenue declines.

• Upside case

  • Any successful brand-level repositioning via access programs.
  • Higher persistence in targeted populations due to better counseling.

Business implication: Use a persistence-adjusted cohort model: new starts are necessary but insufficient. Persistence and switching rates are the main levers for branded performance.

---

What generic entry risks exist for FOSAMAX, and do they affect near-term competition?

Quick answer: Generic risk is not a primary near-term driver because generic competition is already established. Remaining risks are mostly tactical: supply continuity, authorized generic behavior, and payer re-contracting.

Where generic competition can still affect brand

• Contract renegotiations in major PBMs.
• Price alignment across strengths.
• Authorized generic expansion during competitive tendering.

Business implication: Treat generic pressure as a structural cost-down force rather than an event-driven shock.

---

What formulations are protected by FOSAMAX patents, and what are the manufacturing/IP barriers for generics?

Quick answer: For an off-patent platform, manufacturing and formulation barriers typically do not prevent generic manufacturing unless specific formulation-process patents are still listed and enforceable for the relevant dosage form.

Formulation and manufacturing points that can create barriers

• Solid oral dose manufacturing controls (granulation, compression parameters).
• Dissolution profile specifications tied to quality agreements.
• Any remaining formulation-specific claims that are tied to particular excipients or processing steps.

Business implication: Generics face routine CMC and bioequivalence requirements rather than blocking IP.

---

Biosimilar risk and biologics comparison: does FOSAMAX face biosimilar threats?

Quick answer: No. FOSAMAX is a small-molecule bisphosphonate, not a biologic.

---

Key compliance and regulatory status: FDA pathway, labeling, and substitution

Quick answer: As a widely genericized small molecule, regulatory dynamics are dominated by generic labeling parity and substitution rules rather than brand exclusivity.

Regulatory considerations for competitive planning

• Label updates (safety communications) can shift utilization patterns.
• Substitution at the pharmacy depends on state laws and PBM formulary rules.

Business implication: Monitoring safety and labeling changes matters for access. Patent monitoring matters less for future blocking of generics.

---

Key Takeaways

• FOSAMAX (alendronate) is in a mature, generic-dominated market; clinical-trial novelty is limited relative to launch-era bisphosphonate platforms.
• Competitive outcomes are primarily driven by generic pricing, payer preference, and real-world adherence/persistence constraints.
• Patent and exclusivity analysis supports a structural view: brand protection is not a primary forward-looking lever for market growth.
• Projection should be cohort-based (persistence and switching), not purely based on epidemiologic growth or new prescriptions.

---

FAQs

1. Why do patients discontinue alendronate after starting therapy?
   Common drivers include GI intolerance, administration difficulty, and failure to maintain correct dosing technique.

2. Do insurers prefer oral bisphosphonates like FOSAMAX over denosumab or IV zoledronic acid?
   Often yes in lower-risk or cost-sensitive settings, but premium agents can win in populations with adherence issues or high fracture risk.

3. What real-world metrics best predict FOSAMAX persistence?
   Prescription refill-derived persistence, medication possession ratio, and discontinuation timing post-initiation.

4. How do safety warnings for bisphosphonates affect prescribing patterns?
   They can reduce initiation and increase monitoring, particularly in patients with risk factors for rare adverse events.

5. Is there any pathway to grow branded share for an off-patent oral bisphosphonate?
   Growth typically requires access execution (contracting, formulary positioning) and improved adherence support, not patent-driven exclusivity.

---

References

1. FDA. Drug approvals and labels for alendronate products (search portal). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
3. NIH. MedlinePlus: Alendronate information and prescribing guidance. National Library of Medicine. https://medlineplus.gov/